{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:56:43Z","timestamp":1761897403409,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS079200"],"award-info":[{"award-number":["NS079200"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11060-020-03648-9","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T19:05:08Z","timestamp":1609787108000},"page":"193-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma"],"prefix":"10.1007","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0340-2008","authenticated-orcid":false,"given":"Alipi V.","family":"Bonm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec W.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tresa","family":"McGranahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome J.","family":"Graber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"3648_CR1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418","journal-title":"J Clin Oncol"},{"key":"3648_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/neuonc\/noz016","volume":"21","author":"JJ Miller","year":"2019","unstructured":"Miller JJ, Loebel F, Juratli TA et al (2019) Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol 21:669\u2013677","journal-title":"Neuro Oncol"},{"key":"3648_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1227\/NEU.0000000000000753","volume":"77","author":"R Ramakrishna","year":"2015","unstructured":"Ramakrishna R, Hebb A, Barber J et al (2015) Outcomes in reoperated low-grade gliomas. Neurosurgery 77:175\u2013184","journal-title":"Neurosurgery"},{"key":"3648_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","volume":"20","author":"BL McClune","year":"2014","unstructured":"McClune BL, Ahn KW, Wang H-L et al (2014) Allotransplantation for patients age \u226540 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 20:960\u2013968","journal-title":"Biol Blood Marrow Transplant"},{"key":"3648_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722","journal-title":"N Engl J Med"},{"key":"3648_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708","journal-title":"N Engl J Med"},{"key":"3648_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Thiel E, Martus P et al (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80:159\u2013165","journal-title":"J Neurooncol"},{"key":"3648_CR8","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1200\/JCO.2008.17.7089","volume":"27","author":"A Orfao","year":"2009","unstructured":"Orfao A, Quijano S, L\u00f3pez A et al (2009) Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin\u2019s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 27:1462\u20131469","journal-title":"J Clin Oncol"},{"key":"3648_CR9","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: soci\u00e9t\u00e9 fran\u00e7aise de greffe de mo\u00eblle osseuse-th\u00e9rapie cellulaire. J Clin Oncol 26:2512\u20132518","journal-title":"J Clin Oncol"},{"key":"3648_CR10","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/leu.2017.170","volume":"31","author":"B Kasenda","year":"2017","unstructured":"Kasenda B, Ihorst G, Schroers R et al (2017) High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 31:2623\u20132629","journal-title":"Leukemia"},{"key":"3648_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823\u2013833","journal-title":"J Clin Oncol"},{"key":"3648_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/neuonc\/noq011","volume":"12","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 12:736\u2013744","journal-title":"Neuro Oncol"},{"key":"3648_CR13","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061\u20133068","journal-title":"J Clin Oncol"},{"key":"3648_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/neuonc\/nor014","volume":"13","author":"L Nayak","year":"2011","unstructured":"Nayak L, Hedvat C, Rosenblum MK et al (2011) Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol 13:525\u2013529","journal-title":"Neuro Oncol"},{"key":"3648_CR15","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","volume":"10","author":"SR Plotkin","year":"2004","unstructured":"Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin cancer Res 10:5643\u20135646","journal-title":"Clin cancer Res"},{"key":"3648_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","volume":"117","author":"E Pentsova","year":"2014","unstructured":"Pentsova E, DeAngelis LM, Omuro A (2014) Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol 117:161\u2013165","journal-title":"J Neurooncol"},{"key":"3648_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11060-013-1196-1","volume":"115","author":"J-P Zhang","year":"2013","unstructured":"Zhang J-P, Lee EQ, Nayak L et al (2013) Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol 115:71\u201377","journal-title":"J Neurooncol"},{"key":"3648_CR18","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cncr.26709","volume":"118","author":"JJ Raizer","year":"2012","unstructured":"Raizer JJ, Rademaker A, Evens AM et al (2012) Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma. Cancer 118:3743\u20133748","journal-title":"Cancer"},{"key":"3648_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N et al (2017) Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7:1018\u20131029","journal-title":"Cancer Discov"},{"key":"3648_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","volume":"88","author":"K Chamoun","year":"2016","unstructured":"Chamoun K, Choquet S, Boyle E et al (2016) Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series. Neurology 88:101\u2013102","journal-title":"Neurology"},{"key":"3648_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M et al (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) net. Eur J Cancer 117:121\u2013130","journal-title":"Eur J Cancer"},{"key":"3648_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","volume":"118","author":"AJM Ferreri","year":"2011","unstructured":"Ferreri AJM (2011) How I treat primary CNS lymphoma. Blood 118:510\u2013522","journal-title":"Blood"},{"key":"3648_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1212\/WNL.59.5.762","volume":"59","author":"EC Bromberg","year":"2002","unstructured":"Bromberg EC, Siemers J, Taphoorn JB (2002) Is a \u201cvanishing tumor\u201d always a lymphoma? Neurology 59:762\u2013764","journal-title":"Neurology"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-020-03648-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T09:30:37Z","timestamp":1612949437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-020-03648-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3648"],"URL":"https:\/\/doi.org\/10.1007\/s11060-020-03648-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"7 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board (STUDY00006927).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have given consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}